119 results
144
KPRX
Kiora Pharmaceuticals Inc
3 Jun 16
Notice of proposed sale of securities
12:00am
part of the purchase price or other consideration therefor:
Title of
the Class
Date you Acquired
Nature of Acquisition Transaction
Name of Person from … Whom Acquired
(If gift, also give date donor acquired)
Amount of Securities Acquired
Date of Payment
Nature of Payment
Common Stock
Exercise of Stock
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR
ASSERTED AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED ON LICENSEE OR ANY OTHER … , or other action of any nature related to any Licensed Product as manufactured, sold or distributed by Licensee, or a Sublicensee or Affiliate thereof
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
2 Oct 18
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
6:58am
, investigation, or other action of any nature related to any Licensee intellectual property; or (iii) any claim, demand, suit, proceeding, investigation, or other … action of any nature relating to or arising out of Licensee’s action or inaction prior to or after the Effective Date.
(b) Indemnification
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
representing or evidencing such benefits.
8.6 Discretionary Nature of Benefits. The Employee understands that the Employer may amend, change or cancel … , Inventions and Non-Solicitation Agreement.
12. Unique Nature of Agreement; Specific Enforcement. The Employer, EyeGate and the Employee agree
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
of any of its covenants or other obligations hereunder; (ii) any claim, demand, suit, proceeding, investigation, or other action of any nature related … to any Licensor intellectual property; or (iii) any claim, demand, suit, proceeding, investigation, or other action of any nature relating
8-K
EX-10.3
kfp biuir3
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.1
my6je3
24 Mar 20
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
47vnj9nlapgm 9qn
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-2.1
yvqh 0v3v
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
ya0sbz5
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
44n099qehsdxa2qixn
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.2
6vijsc11trjgpsp4
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
D
9on47ess
21 Dec 09
$22.64M in equity, sold $11.08M, 20 investors
12:00am
DRSLTR
5s0ixt2vqpr18l2
7 Jul 14
Correspondence regarding draft registration statement
12:00am
D
gp9a0aj
26 Sep 13
$1.45M in debt, sold $968.97K, 21 investors
12:00am
D
b8bmyhdt7
15 Jan 20
Indefinite amount in options / securities to be acquired, 5 investors
4:15pm
DRS/A
EX-10.10
fhtjv
8 Jul 14
Draft registration statement (amended)
12:00am
D
a9xsy7x9cqkudz4v8b
4 Nov 21
Indefinite amount in equity, sold $67.26K, 6 investors
4:20pm
D
s10na1uzd5u
5 Jan 11
$4.45M in equity, sold $4.45M, 9 investors
12:00am